Indivior Pharmaceuticals
INDV
290 hedge funds and large institutions have $3.89B invested in Indivior Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 98 increasing their positions, 86 reducing their positions, and 49 closing their positions.
104.82% more ownership
Funds ownership: 0% → 104.82% (+105%)
69% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 49
41% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $9.58M
14% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 86
12% more funds holding
Funds holding: 259 → 290 (+31)
11% less capital invested
Capital invested by funds: $4.36B → $3.89B (-$465M)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$74.6M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$46.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$42.1M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$38.8M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
-$74.8M |
| 2 |
MAP
Madison Avenue Partners
New York
|
-$64.9M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$60.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$57M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$55.9M |
INDV Hedge Fund Activity: Q1 2026 in Review
290 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q1 2026, worth a combined $3.89B — down 11% from $4.36B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new INDV positions and 49 closed out — a net gain of 34 holders — while 98 added to existing stakes and 86 trimmed.
The largest buyer was Millennium Management, adding an estimated $74.6M. The largest seller was Divisadero Street Capital Management, cutting an estimated $74.8M.
- 290 institutional investors held Indivior Pharmaceuticals (INDV) as of Q1 2026, up from 259 in Q4 2025.
- Funds reported $3.89B of Indivior Pharmaceuticals stock for Q1 2026, down 11% quarter-over-quarter.
- 83 funds opened new Indivior Pharmaceuticals positions in Q1 2026 and 49 closed out, a net change of +34 holders.
- The largest Indivior Pharmaceuticals buyer in Q1 2026 was Millennium Management, an estimated $74.6M added.
- The largest Indivior Pharmaceuticals seller in Q1 2026 was Divisadero Street Capital Management, an estimated $74.8M sold.
Based on aggregated 13F filings for Q1 2026.